Does Varenicline Work for Quitting Vaping?

If you’ve tried to quit vaping and found it brutally difficult, you’re not imagining things. The nicotine delivery from modern vapes is fast, potent, and deeply habit-forming. That’s led many people to ask: does varenicline for vaping actually work? Can you get a prescription for Chantix for vaping the same way smokers have for years? The honest answer is that the science is still catching up — but recent trial data on a closely related drug is genuinely encouraging.

Let’s walk through what we know, what we don’t, and what the latest Phase 2 trial results mean for anyone trying to break free from nicotine vapes.

A quick primer: what is varenicline?

Varenicline (sold under the brand name Champix in the UK, formerly Chantix in the US before its withdrawal from that market) is a prescription medication originally developed for smoking cessation. It works as a partial agonist at the nicotinic acetylcholine receptor — the same receptor that nicotine from cigarettes or vapes binds to.

In plain terms, varenicline does two things simultaneously:

1. It partially activates the nicotine receptor, which reduces cravings and eases withdrawal symptoms.
2. It blocks nicotine from fully binding, so if you do vape or smoke while taking it, the “hit” feels blunted and unsatisfying.

This dual mechanism made varenicline one of the most effective pharmacological aids for cigarette smoking cessation. Multiple large trials showed it roughly tripled quit rates compared to placebo. For smokers, it was a genuine breakthrough.

But here’s the catch: virtually all of that evidence was gathered in cigarette smokers, not vapers. The two habits overlap — both deliver nicotine — but they differ in delivery speed, dosing patterns, behavioural triggers, and user demographics. Most vapers are younger, became addicted through a different route, and may have never smoked a cigarette in their life.

So the question isn’t whether varenicline works for nicotine addiction in general. It’s whether the existing evidence translates to the specific context of vaping.

Why the evidence gap matters

Until very recently, there were no randomised controlled trials of any prescription medication specifically for vaping cessation. Zero. Doctors who prescribed varenicline to vapers were extrapolating from smoking data — a reasonable clinical judgement, but not the same as having direct evidence.

This matters because vaping cessation has its own particular challenges. If you’ve read our guide to vaping withdrawal symptoms, you’ll know that the withdrawal profile can be intense: irritability, anxiety, difficulty concentrating, and powerful cravings that arrive in waves. The behavioural component is different too — vaping is often more continuous and habitual than cigarette smoking, with no natural “end point” like stubbing out a cigarette.

Understanding how nicotine affects the brain helps explain why medications like varenicline are appealing in theory. Nicotine rewires your dopamine pathways regardless of how it arrives. A drug that can dampen those pathways should help whether the nicotine came from a Marlboro or a disposable vape. But “should” and “does” are different words, and medicine rightly demands evidence before making strong claims.

That’s what makes the cytisinicline trial so noteworthy.

The cytisinicline Phase 2 trial: what actually happened

In 2025, results were published from a Phase 2 randomised, double-blind, placebo-controlled trial of cytisinicline (also known as cytisine) specifically for e-cigarette cessation. This is the first rigorous trial of a nicotinic receptor partial agonist designed and powered for vapers rather than smokers.

Cytisinicline is pharmacologically related to varenicline — both are partial agonists at the same receptor, and cytisinicline is actually the older compound. It’s been used in Eastern Europe for decades as a smoking cessation aid (marketed as Tabex) and is now being developed under the name cytisinicline by Achieve Life Sciences for Western markets.

Here are the headline numbers:

• 31.8% of participants in the cytisinicline group achieved continuous abstinence from e-cigarettes during the final four weeks of the treatment period.
• The placebo group’s quit rate was significantly lower.
• The drug was generally well tolerated, with nausea being the most common side effect (consistent with the known profile of nicotinic receptor partial agonists).

A 31.8% quit rate might not sound extraordinary at first glance, but context matters enormously. In smoking cessation trials, varenicline typically achieves quit rates of 25-35% at 12 weeks — so cytisinicline’s performance in vapers is squarely within the range that made varenicline a first-line treatment for smoking.

This is genuinely significant. It’s the first strong signal that this class of medication works for vaping cessation specifically, not just by inference from cigarette data.

What this means (and what it doesn’t)

Let’s be precise about what we can and can’t take from this trial.

What we can say:

• A nicotinic receptor partial agonist has now shown efficacy specifically for vaping cessation in a properly designed trial.
• The effect size is clinically meaningful and comparable to what we see with varenicline in smokers.
• This strengthens the rationale for doctors who are already prescribing varenicline off-label to vapers.
• It adds momentum to the regulatory pathway for cytisinicline as a licensed treatment.

What we can’t say yet:

• This was a Phase 2 trial — important, but not the final word. Phase 3 trials with larger sample sizes and longer follow-up are needed before regulatory approval.
• We don’t know the long-term quit rates. Smoking cessation research consistently shows that many people who are abstinent at 12 weeks relapse by 6 or 12 months. The same may apply here.
• The trial studied cytisinicline, not varenicline directly. While the drugs share a mechanism, they’re not identical. Direct evidence for varenicline in vapers remains limited to smaller studies and clinical experience.
• We don’t know how these medications interact with different vaping patterns — someone using a low-nicotine pod system may respond differently than someone on high-strength disposables.

So should you ask your doctor about varenicline?

If you’re struggling to quit vaping and behavioural approaches alone haven’t worked, it’s entirely reasonable to discuss pharmacological options with your GP. Here’s what that conversation might look like:

Varenicline (Champix): Your doctor may be willing to prescribe this off-label for vaping cessation. The evidence base is indirect — drawn from smoking trials — but the pharmacological rationale is sound, and the cytisinicline trial strengthens the case that this drug class works for vapers. Availability may vary; supply issues have affected varenicline in some markets.

Nicotine replacement therapy (NRT): Patches, gum, lozenges, and mouth sprays remain the most accessible pharmacological option. Our complete guide to nicotine replacement therapy covers how to use these effectively. The evidence for NRT in vaping cessation is also extrapolated from smoking data, but many clinicians use it as a first-line approach — particularly combination therapy (patch plus a short-acting form).

Bupropion: Another prescription option originally developed as an antidepressant. It works through a different mechanism (norepinephrine-dopamine reuptake inhibition) and has solid evidence for smoking cessation. Again, direct evidence for vaping cessation is thin, but it’s another tool in the kit.

The key point: pharmacological support exists, even if the evidence base is still being built for vaping specifically. Don’t let the perfect be the enemy of the good. If you’ve tried to quit cold turkey and it hasn’t stuck — and our piece on cold turkey versus tapering explores why that happens — medication may be the difference-maker.

The bigger picture: combining medication with behavioural support

One thing that smoking cessation research has shown consistently is that medication works best when combined with behavioural support. Varenicline alone is good. Varenicline plus counselling or a structured quit programme is better.

The same logic applies to vaping cessation. Medication can take the edge off withdrawal and reduce the intensity of cravings, but it doesn’t address the habits, triggers, and emotional patterns that keep you reaching for your vape.

That’s exactly why we built Cravo — to provide the behavioural side of the equation. The app helps you understand your craving patterns, build alternative responses, and track your progress in a way that keeps motivation visible on the hard days. If you’re considering medication, having a structured programme alongside it could meaningfully improve your chances.

Check out our guide to quitting vaping for a complete overview of approaches, or join Cravo to be among the first to access the app when it launches.

What about the money side?

One practical consideration worth mentioning: vaping is expensive, and quitting frees up real money. If you’re weighing up the cost of a GP appointment or a prescription against the ongoing cost of vapes, our savings calculator can help you see the numbers clearly. Most people are surprised by how much they spend annually on vaping — and how quickly the savings accumulate once they stop.

A course of varenicline or cytisinicline (when available) is a finite cost. Vaping, if you continue, is an indefinite one.

Frequently asked questions

Is varenicline (Champix) licensed for vaping cessation?

No. Varenicline is currently licensed for smoking cessation only. Any prescription for vaping cessation would be off-label — meaning the doctor is using clinical judgement to prescribe outside the drug’s formal indication. This is legal and common in medicine, but it means you should have a frank discussion with your prescriber about the evidence and their reasoning.

Is cytisinicline available yet?

Not in most Western markets as of early 2026. Cytisinicline (as cytisine) has been available in some Eastern European countries for decades, but it’s still working through the regulatory process in the UK, US, and other major markets. The Phase 2 trial results should accelerate this, but Phase 3 trials and regulatory review take time. If you’re interested in this option, ask your doctor about the current status in your country.

Can I use NRT and varenicline together?

This is a clinical decision that depends on your individual circumstances. Some smoking cessation guidelines have cautioned against combining NRT with varenicline due to increased side effects (particularly nausea), while others note that combination use may be safe and potentially more effective. Do not combine medications without medical guidance. Your GP or a smoking cessation service can advise on what’s appropriate for you.

What are the main side effects of varenicline?

The most common side effects are nausea (which tends to improve over the first couple of weeks), vivid dreams, headache, and insomnia. Historical concerns about neuropsychiatric side effects (mood changes, suicidal ideation) led to a black-box warning in the US that was later removed after large safety trials found no significant increased risk. However, anyone with a history of mental health conditions should discuss this carefully with their prescriber.

How long does a course of varenicline last?

A standard course is 12 weeks, with the option to extend to 24 weeks for people who have successfully quit and want additional support to prevent relapse. You typically start the medication 1-2 weeks before your target quit date, gradually increasing the dose.

Are there any options if I can’t access prescription medication?

Yes. Nicotine replacement therapy is available over the counter in most countries. Behavioural support — whether through apps like Cravo, quitlines, or counselling — has its own evidence base and can be effective alone or in combination with NRT. Our guide to quitting vaping outlines multiple approaches for different situations.

The research trajectory

The vaping cessation field is where smoking cessation was perhaps 20 years ago — we know nicotine addiction is the core problem, we have plausible pharmacological tools, and now we’re building the specific evidence base. The cytisinicline Phase 2 results are a meaningful step in that trajectory.

Expect to see more trials in the next few years. Researchers are also investigating whether different vaping populations (daily vs. intermittent, high-nicotine vs. low-nicotine, adolescents vs. adults) respond differently to medication. The answers will matter.

In the meantime, don’t wait for perfect evidence to take action. The tools available right now — NRT, behavioural support, and potentially off-label varenicline — are genuine options. Talk to your doctor. Build a quit plan. Use every advantage you can find.

---

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting or changing any medication. The information about cytisinicline is based on published Phase 2 trial data and should not be interpreted as an endorsement of any unapproved treatment. If you are experiencing mental health difficulties, contact your GP or a crisis helpline immediately.

---

“The best time to quit was before you started. The second best time is right now — and you have more tools to help than you think.”

Ready to take the next step? Join Cravo and get support that works alongside whatever cessation method you choose.